/ /

  • linkedin
  • Increase Font
  • Sharebar

    New pathways to cancer therapy

    Repurposed antifungal agent exhibits promising efficacy and safety for BCCNS treatment


    Regulatory status report

    HedgePath plans to submit a complete background package for its phase IIb study results to the FDA by the middle of June, and the agency has indicated it plans to provide a written response by the end of July 2017 with further guidance on steps necessary for completing the study and reporting final data. 






    Frank E. O’Donnell Jr., MD
    E: [email protected]
    Dr. O’Donnell is a consultant to HedgePath Pharmaceuticals and a shareowner.

    Nick Virca
    E: [email protected]
    Virca is an employee of and owns shares in HedgePath Pharmaceuticals.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results